Geron (GERN)
(Delayed Data from NSDQ)
$3.87 USD
+0.14 (3.75%)
Updated May 7, 2024 04:00 PM ET
After-Market: $3.86 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Geron Corporation [GERN]
Reports for Purchase
Showing records 181 - 200 ( 236 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
New Management - New Focus - New Execution - Imetelstat on Track for New Data
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.